Articles

Amgen, Novartis expand deal to commercialize migraine drug candidate

The expansion builds on the companies' 2015 global collaboration in neuroscience
Written byKelsey Kaustinen
| 3 min read

BASEL, Switzerland & THOUSAND OAKS, Calif.—Novartis and Amgen are doubling down on a 2015 collaboration in neuroscience with news of an expanded agreement to commercialize AMG 334 (erenumab), Amgen's drug candidate in development for preventing migraine. Under the expanded agreement, the companies will co-commercialize AMG 334 in the United States, with Amgen retaining exclusive commercialization rights in Japan while Novartis retains exclusive rights to commercialize the drug in the rest of the world and gains commercialization rights in Canada. Amgen and Novartis will continue to co-develop the program.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.